Bayer’s Stock Teeters on Two Knife Edges: A $2.45 Billion Biotech Bet and a Supreme Court Ruling

Bayer awaits Supreme Court glyphosate ruling in Durnell case and EU/US approval for stroke drug Asundexian, while stock hovers near €38 amid pipeline push and legal overhang.

The next few weeks will be anything but routine for Bayer. The German drug and crop-science group finds itself waiting on two defining events simultaneously: a U.S. Supreme Court verdict in the glyphosate case Durnell and regulatory decisions on its next-generation stroke drug Asundexian. Both carry the potential to rewrite the investment case for a stock that has been drifting in a narrow range, recently trading at around €38.07 to €38.26.

Investors who have watched Bayer’s shares climb 44.90% over the past twelve months — yet only 0.62% since the start of 2026 — know that the market has already priced in some operational progress but is holding its fire on the legal and pipeline fronts. The 50-day moving average sits at €37.76, and the 100-day average of €39.64 acts as immediate resistance. With a relative strength index of 58 and an annualised 30-day volatility near 32%, the chart signals indecision rather than conviction.

A Biotech Bet With Real Money on the Table

On June 17, Bayer closed the acquisition of Perfuse Therapeutics, securing full global rights to PER-001, a Phase-II endothelin receptor antagonist targeting glaucoma and diabetic retinopathy. The deal carries a headline value of up to $2.45 billion, anchored by a $300 million upfront payment and milestones tied to development and sales. The ophthalmology portfolio, heavily dependent on the ageing blockbuster Eylea, urgently needs new blood. PER-001, if successful, could fill that gap — but a Phase-II candidate is far from a sure thing, and the path to market remains long.

That biotech bet is part of a broader pipeline push. Bayer has filed for European approval of Asundexian, a Factor XIa inhibitor designed to prevent ischaemic stroke, and claims it is the first such submission in Europe. Both the U.S. Food and Drug Administration and China’s National Medical Products Administration have granted priority review. The significance is hard to overstate: with Xarelto facing patent expiry, Asundexian is the designated successor. A green light from regulators would fundamentally shift the narrative around Bayer’s pharma division.

The Supreme Court Wild Card

But no amount of pipeline optimism can fully offset the legal overhang. The Supreme Court is expected to rule this month in Durnell, a case that challenges whether a U.S. state can impose penalties on a product the Environmental Protection Agency has deemed safe. A victory for Bayer would effectively neutralise roughly 65,000 outstanding glyphosate lawsuits. UBS analyst Matthew Weston puts the odds of such an outcome at 70%. Should the ruling go the other way, the debt burden — already €32.5 billion at the end of March — would remain under severe pressure from ongoing litigation costs.

Finance chief Wolfgang Nickl has already flagged that legal cash outflows could hit around €5 billion in 2026 alone, pushing free cash flow into negative territory of €1.5 billion to €2.5 billion. In the first quarter, litigation expenses came to roughly €2 billion. Meanwhile, a group of shareholders continues to push for a breakup of the conglomerate, arguing that a spin-off of the Consumer Health division would unlock value. That pressure is not going away.

Political Headwinds From Washington

On top of the courtroom drama, a trade investigation adds another layer of uncertainty. The U.S. Trade Representative has launched an inquiry under the Trade Act into German drug-pricing practices, accusing Berlin of suppressing medicine prices artificially. The worst-case scenario — punitive tariffs on German pharmaceuticals — would directly hit Bayer’s export business. A final decision is not expected before a public hearing in September, but the mere threat is enough to keep the stock in check.

What Could Break the Deadlock?

Bayer’s own guidance points to a roughly stable overall performance in 2026, with stronger contributions from agriculture and consumer health compensating for a weaker pharma result. The company aims to return its pharma division to mid-single-digit growth from 2027 and expand operating margins to around 30% by 2030. Those targets are underpinned by concrete clinical and regulatory milestones, including Nubeqa and Kerendia, which are already delivering meaningful revenue gains.

Yet the market is waiting for binary triggers. A positive Supreme Court ruling would shift attention back to operational strengths and pipeline value. A negative one would reinforce fears about the debt spiral. Asundexian approval in the second half of 2026 could be the catalyst that unlocks a re-rating — but until then, Bayer’s stock remains suspended between a promising pipeline and a legal quagmire that shows no sign of clearing.